AI-generated analysis. Always verify with the original filing.
SAB Biotherapeutics, Inc. furnished additional data from its Phase 1 clinical trial of HUman anti-thymocyte biologic under Item 7.01 via Exhibits 99.1 and 99.2, and announced this under Item 8.01 on March 10, 2026. The press release in Exhibit 99.1 details the first-in-human trial results.
Event Type
Disclosure
Voluntary
Variant
8-K
, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
Other Events. On March 10, 2026, the Company announced additional data from its Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of
Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release issued by SAB Biotherapeutics, Inc. dated March 10, 2026 (furnished herewith).